Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
Author:
Jiménez de Ory Santiago1ORCID, Beltrán-Pavez Carolina2, Gutiérrez-López Miguel2, Santos María Del Mar3, Prieto Luis4, Sainz Talía5, Guillen Sara6, Aguilera-Alonso David3, Díez Cristina7, Bernardino Jose Ignacio8ORCID, Mellado María José5, Ramos José Tomás9, Holguín África2, Navarro Marisa10, Mellado María José, Escosa Luis, Hortelano Milagros García, Sainz Talía, Rojo Pablo, Prieto-Tato Luis, Epalza Cristina, Ramos José Tomás, Illán Marta, Guillén Sara, Navarro María Luisa, Saavedra Jesús, Santos Mar, Santiago Begoña, de Ory Santiago Jimenez, Carrasco Itzíar, Berzosa Arantxa, Aguilera David, Muñoz-Fernández Maria Angeles, Roa Miguel Ángel, Penín María, Martínez Jorge, Badillo Katie, Jiménez Ana Belén, Navas Adriana, Oñate Eider, Pocheville Itziar, Garrote Elisa, Colino Elena, Sirvent Jorge Gómez, Garzón Mónica, Román Vicente, Angulo Raquel, Neth Olaf, Falcón Lola, Terol Pedro, Santos Juan Luis, Vázquez Álvaro, Moreno David, Lendínez Francisco, Peromingo Estrella, Ruiz Beatriz, Grande Ana, Romero Francisco José, Pérez Carlos, Lillo Miguel, Losada Begoña, Herranz Mercedes, Bustillo Matilde, Lafuente Miguel, Collado Pilar, Couceiro José Antonio, Vila Leticia, Calviño Consuelo, Piqueras Ana Isabel, Oltra Manuel, Gavilán César, Montesinos Elena, Dapena Marta, Álvarez Cristina, Jiménez Beatriz, Andrés Ana Gloria, Marugán Víctor, Ochoa Carlos, Menasalvas Ana Isabel, Cervantes Eloísa, Soler-Palacín Pere, Frick Maria Antoinette, Mur Antonio, Lopez Nuria, Mendez María, Mayol Lluıs, Vallmanya Teresa, Calavia Olga, García Lourdes, Coll María Teresa, Pineda Valentí, Rius Neus, Dueñas Joaquín, Fortuny Clàudia, Bernardino Antoni Noguera-Julian Ignacio, Montes María Luisa, Valencia Eulalia, Rubio Rafael, Pulido Federico, Bisbal Otilia, Alonso Gabriel Gaspar, Berenguer Juan, Díez Cristina, Aldamiz Teresa, Montilla Pedro, Bermúdez Elena, Valerio Maricela, Sanz José, Arponen Sari, Gimeno Alejandra, Cervero Miguel, Torres Rafael, Moreno Santiago, Pérez Ma Jesús, del Campo Santos, Ryan Pablo, Troya Jesús, Sanz Jesús, Losa Juan, Gómez Rafael, Górgolas Miguel, Iribarren José Antonio, Rodríguez Francisco, Pascual Lydia, Aramburu María José, Goikoetxea Ane Josune, Muñoz Josefa, Ibarra Sofía, Hernández Michele, Sirvent Juan Luis Gómez, Rodríguez Jehovana, Cárdenes Miguel Ángel, López-Cortés Luis Fernando, Roca Cristina, Llaves Silvia, Ríos María José, Rodríguez Jesús, Palomo Virginia, Pasquau Juan, García Coral, Hernández José, Martínez Clara, Rivero Antonio, Camacho Ángela, Merino Dolores, Corpa Laura, Martínez Elisa, Mateos Fernando, Blanch José Javier, Torralba Miguel, Arazo Piedad, Samperiz Gloria, Miralles Celia, Ocampo Antonio, Pousada Guille, Mena Álvaro, Montero Marta, Salavert Miguel, Castro Iván, Cuéllar Sandra, Galindo María José, Ferrando Ramón, Portilla Joaquín, Portilla Irene, Gutiérrez Félix, Masiá Mar, Robledano Cati, Adsuar Araceli, Hinojosa Carmen, Abadía Jésica, Galera Carlos, Albendín Helena, Fernández Marian, Blanco José Ramón, Burgos Joaquín, Torres Berta, de Lazzari Elisa,
Affiliation:
1. Hospital General Universitario Gregorio Marañón, Fundación para la Investigación Biomédica, Instituto de Investigación Gregorio Marañón (IiSGM), Madrid, Spain 2. HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, Hospital Ramón y Cajal-IRYCIS and CIBEREsp-RITIP, Madrid, Spain 3. Pediatric Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiGM), Madrid, Spain 4. Department of Infectious Diseases, Hospital 12 de Octubre, Madrid, Spain 5. Department of Infectious Diseases and Tropical Pediatrics, Hospital La Paz, Madrid, Spain 6. Department of Pediatrics, Hospital de Getafe, Getafe, Spain 7. Infectious Diseases/HIV Unit, Hospital General Universitario Gregorio Marañón, Fundación para la Investigación Biomédica, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain 8. Infectious Diseases Unit, Hospital La Paz-Carlos III-Cantoblanco, Madrid, Spain 9. Department of Infectious Diseases, Hospital Clínico Universitario and Universidad Complutense, Madrid, Spain 10. Pediatric Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Gregorio Marañón (IiSGM) and RITIP, Madrid, Spain
Abstract
Abstract
Objectives
We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples.
Methods
We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank. Genomic DNA was extracted from PBMCs and HIV-1 RT gene was amplified and sequenced for resistance testing by Stanford HIV Resistance tool.
Results
Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6–23.1) with 4 years (IQR 2.1–6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.
Conclusions
The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.
Funder
Instituto de Salud Carlos III of Spain European Development Regional Fund Spanish National AIDS Network Instituto de Salud Carlos III Spanish Health Ministry CIBERESP Red de Investigación Translacional en Infectología Pediátrica Spanish Ministry of Health European Union Contrato Río Hortega
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference21 articles.
1. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010;Charpentier;J Antimicrob Chemother,2013 2. Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses;Rojas Sánchez;Clin Microbiol Infect,2015 3. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials;Cahn;Lancet,2019 4. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study;van Wyk;Clin Infect Dis,2020 5. New strategies of ARV: the road to simplification;de Miguel Buckley;Curr HIV/AIDS Rep,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|